CryoLife, Inc. Earnings Conference Call (Q4 2012)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 14 Calls Today's Calls

Call Details CryoLife, Inc. Earnings Conference Call (Q4 2012) Scheduled to start Thu, Feb 14, 2013, 10:00 am Eastern -- this event is ongoing now-- Listen to the ongoing live event audio stream About CryoLife Inc (NYSE:CRY) Other Calls  CryoLife, Inc. engages in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries in the United States and Canada. Its CryoValve SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The company’s CryoPatch SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract, a surgery commonly performed in children with congenital heart defects, such as tetralogy of Fallot, truncus arteriosus, and pulmonary atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch. CryoLife’s BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels. BioGlue is also CE Marked in the European community and approved in Canada and Australia for use in soft tissue repair. The company’s BioFoam Surgical Matrix is CE Marked in the European community for use as an adjunct in the sealing of abdominal parenchymal tissues when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty in reconstructive plastic surgery. CryoLife also distributes HemoStase, a hemostatic agent for use in cardiac and vascular surgery, as well as in various international markets for cardiac, vascular, and general surgery. The company distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. CryoLife was founded in 1984 and is headquartered in Kennesaw, Georgia. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings